Understand the source comparison
Peptides Help With Focus: Full Comparison
The table below compares cognitive peptides across mechanism, administration, timeline, and evidence quality. Providing clarity on which compounds warrant consideration for focus-related research. Cerebrolysin BDNF/CNTF upregulation, neuroprotection Intravenou
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares cognitive peptides across mechanism, administration, timeline, and evidence quality. Providing clarity on which compounds warrant consideration for focus-related research.
- Cerebrolysin
- BDNF/CNTF upregulation, neuroprotection
- Intravenous 10–30ml daily for 10–20 doses
- 3–4 weeks
- High. Multiple RCTs in stroke and dementia populations
- Most evidence-backed option for structural cognitive deficits; expensive and requires IV access
- Dihexa
- HGF/c-Met receptor activation, synaptogenesis
- Oral 5–10mg daily
- 2–3 weeks
- Low. Animal data only; no human RCTs
- Promising mechanistically but lacks safety data; confined to research settings
- P21
- CNTF-derived neurogenesis promoter
- Intranasal 5–10mg weekly
- 4–6 weeks
- Very low. Anecdotal only
- Experimental; no formal trials; used by researchers interested in hippocampal function
- Semax
- BDNF modulation, dopaminergic enhancement
- Intranasal 0.1–0.5mg daily
- Moderate. Russian trials; limited Western replication
- Potentially useful for attentional fatigue; evidence base limited outside Eastern Europe